These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35676372)

  • 1. Nusinersen treatment response markers.
    Fyfe I
    Nat Rev Neurol; 2022 Jul; 18(7):381. PubMed ID: 35676372
    [No Abstract]   [Full Text] [Related]  

  • 2. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
    Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
    Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
    [No Abstract]   [Full Text] [Related]  

  • 3. Nusinersen treatment in a type 3 spinal muscular atrophy patient during early pregnancy.
    Schön M; Domingues S; de Carvalho M; Oliveira Santos M
    Neurol Sci; 2023 May; 44(5):1803-1804. PubMed ID: 36645532
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy.
    Ferrante L; Melendez-Zaidi A; Lindsey W; Lotze T
    Muscle Nerve; 2022 Aug; 66(2):E8-E10. PubMed ID: 35616550
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating adults with spinal muscular atrophy with nusinersen.
    Farrar MA; Kiernan MC
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1139. PubMed ID: 32917825
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1.
    Bruno G; Donnarumma B; Inverardi A; Buonpensiero P; Sepe A; Tosco A; Raia V; Varone A
    Pediatr Pulmonol; 2021 Jun; 56(6):1806-1808. PubMed ID: 33684256
    [No Abstract]   [Full Text] [Related]  

  • 7. Spinal muscular atrophy: state of the art and new therapeutic strategies.
    Messina S; Sframeli M; Maggi L; D'Amico A; Bruno C; Comi G; Mercuri E
    Neurol Sci; 2022 Dec; 43(Suppl 2):615-624. PubMed ID: 33871750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen helps restore walking ability in childhood spinal muscular atrophy.
    Sugimoto M; Aiba K; Koyama N; Yokochi K; Nishio H
    Pediatr Int; 2019 Jul; 61(7):728-729. PubMed ID: 31290219
    [No Abstract]   [Full Text] [Related]  

  • 9. [Nusinersen in the treatment of spinal muscular atrophy].
    Sinkó G; Kiss Z; Kalman B
    Ideggyogy Sz; 2018 Mar; 71(3-04):90-94. PubMed ID: 29889467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy.
    Chacko A; Sly PD; Gauld L
    Am J Respir Crit Care Med; 2020 Mar; 201(5):624. PubMed ID: 31747298
    [No Abstract]   [Full Text] [Related]  

  • 12. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy.
    Salmin F; Albamonte E; Morettini V; Gagliano N; Mercuri E; Sansone VA
    Muscle Nerve; 2019 Jun; 59(6):E42-E44. PubMed ID: 30811610
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Chacko
    LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
    Am J Respir Crit Care Med; 2020 Mar; 201(5):624-626. PubMed ID: 31747301
    [No Abstract]   [Full Text] [Related]  

  • 16. Respiratory assessment in a spinal muscular atrophy infant treated with nusinersen.
    Ogawa K; Okanari K; Kobayashi O; Nakashima M; Ihara K
    Pediatr Int; 2019 Oct; 61(10):1051-1053. PubMed ID: 31612561
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].
    Mao SS; Feng YJ; Xu L; Yao M; Xia Y; Jin JN; Wang LS; Chen TT; Chen XY; Zhang Y; Zhang H; Jiang Y; Li HB; Long Q; Gao F
    Zhonghua Er Ke Za Zhi; 2022 Jul; 60(7):688-693. PubMed ID: 35768357
    [No Abstract]   [Full Text] [Related]  

  • 18. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
    Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
    N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.